Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inmune Bio (INMB) Current Leases (2019 - 2025)

Inmune Bio's Current Leases history spans 7 years, with the latest figure at $457000.0 for Q3 2025.

  • For Q3 2025, Current Leases rose 238.52% year-over-year to $457000.0; the TTM value through Sep 2025 reached $457000.0, up 238.52%, while the annual FY2024 figure was $140000.0, 17.65% up from the prior year.
  • Current Leases for Q3 2025 was $457000.0 at Inmune Bio, up from $220000.0 in the prior quarter.
  • Across five years, Current Leases topped out at $457000.0 in Q3 2025 and bottomed at $36000.0 in Q2 2021.
  • The 5-year median for Current Leases is $119000.0 (2023), against an average of $140733.3.
  • The largest annual shift saw Current Leases surged 417.99% in 2021 before it tumbled 35.56% in 2022.
  • A 5-year view of Current Leases shows it stood at $135000.0 in 2021, then plummeted by 35.56% to $87000.0 in 2022, then soared by 36.78% to $119000.0 in 2023, then grew by 17.65% to $140000.0 in 2024, then surged by 226.43% to $457000.0 in 2025.
  • Per Business Quant, the three most recent readings for INMB's Current Leases are $457000.0 (Q3 2025), $220000.0 (Q2 2025), and $140000.0 (Q4 2024).